Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PharmaCyte Biotech, Inc. - Common Stock (NQ:PMCB)

0.9769 +0.0171 (+1.78%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PharmaCyte Biotech, Inc. - Common Stock

< Previous 1 2 Next >
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
From PharmaCyte Biotech, Inc.
Via Business Wire
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
From Femasys Inc.
Via GlobeNewswire
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Final Results of Tender Offer
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
From PharmaCyte Biotech
Via Business Wire
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
From PharmaCyte Biotech, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.